## CL: Colgate-Palmolive Company - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_10 -1.5% below STRENGTH zone (3.0-6.0%); PEG 1.60 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($74.31)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. NewEdge Advisors LLC Raises Stake in Colgate-Palmolive Company $CL**
- Source: MarketBeat | 20251210T131017 | Somewhat-Bullish | Relevance: 99%
-  NewEdge Advisors LLC has increased its stake in Colgate-Palmolive Company (NYSE:CL) by 5.9%, now owning 501,412 shares valued at approximately $45.58 million. This increase contributes to the overall institutional ownership of Colgate-Palmolive, which stands at 80.41%. The company recently reported quarterly earnings per share of $0.91, beating estimates, and maintains a "Moderate Buy" consensus rating from analysts.

**2. Federated Hermes Inc. Has $42.44 Million Stake in Colgate-Palmolive Company $CL**
- Source: MarketBeat | 20251209T100812 | Neutral | Relevance: 99%
-  Federated Hermes Inc. decreased its stake in Colgate-Palmolive Company (NYSE:CL) by 22.2% during the second quarter, still holding 466,895 shares worth $42.44 million. Other institutional investors have adjusted their holdings, with 80.41% of the company's stock owned by institutional investors and hedge funds. Analyst ratings for Colgate-Palmolive currently lean towards a "Moderate Buy" with an average price target of $89.87.

**3. Colgate-Palmolive's (CL) Hold Rating Reaffirmed at Argus**
- Source: MarketBeat | 20251211T141811 | Neutral | Relevance: 99%
- Argus has reaffirmed a "hold" rating on Colgate-Palmolive (CL), with overall analyst coverage remaining mixed, indicating a consensus rating of "Moderate Buy" and a price target of $89.00. The company recently reported Q3 EPS of $0.91, exceeding estimates, but revenue missed expectations at $5.13 billion. Investors should note the company's P/E of 21.75, low liquidity, and substantial institutional ownership.

**4. RBC’s Confidence in Colgate-Palmolive’s Margins and Cash Flow Might Change The Case For Investing In CL**
- Source: Simply Wall Street | 20251210T024611 | Bullish | Relevance: 99%
-  RBC Capital has upgraded Colgate-Palmolive to Outperform, citing strong revenue, pricing power, and high gross margins, alongside robust free cash flow generation. This upgrade reinforces the existing investment narrative that Colgate-Palmolive (CL) can convert brand strength and pricing power into steady cash flow. The company’s share repurchase program further highlights its strong cash generation, although risks remain from rising palm oil and packaging costs.

**5. Natixis Sells 21,369 Shares of Colgate-Palmolive Company $CL**
- Source: MarketBeat | 20251209T123612 | Neutral | Relevance: 99%
- Natixis reduced its stake in Colgate-Palmolive Company (NYSE:CL) by 12.5% in the second quarter, selling 21,369 shares and retaining 149,051 shares valued at $13.55 million. The stock currently holds a "Moderate Buy" consensus rating with an average target price of $89, despite recent price target reductions from several major analysts. Colgate-Palmolive pays a quarterly dividend of $0.52, resulting in an annualized yield of approximately 2.7%, and recently beat EPS estimates while slightly missing revenue expectations in its last quarterly report.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Argus Research | $0 | $0 | 0% |
| 2025-12-09 | RBC Capital | $88 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Argus Research | down | Hold |
| 2025-12-09 | RBC Capital | up | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.07M) |
| Sells | 15 ($1.13M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.8% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.2%)
- Blackrock Inc.: 8.6% (+0.5%)
- State Street Corpora: 6.0% (+0.2%)
- Price (T.Rowe) Assoc: 4.0% (-11.5%)
- Geode Capital Manage: 2.7% (+4.1%)

### Key Risks

1. Long-term trend broken: trading 10.3% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.60 elevated, pricing in significant growth expectations. Forward P/E 20.1x stretched relative to 5% growth. Quality metrics strong (ROE 294%, ROA 15%). Balance sheet: $1.1B free cash flow. Insider selling cluster ($1.1M in 90 days), potential headwind. Institutional flow bearish (5 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $62.4B |
| Beta | 0.29 |
| 52W Range | $74.55 - $100.18 |
| Short Interest | 2.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.60 |
| Forward P/E | 20.1 |
| Current P/E | 21.1 |
| YoY Growth | 5.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -3.2% to -1.5% (+1.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.5pp (needs >3.0% for momentum thesis). Below SMA200 (0.90x), long-term trend not supportive. RSI neutral at 45.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.52% (CS: 22) | Neutral |
| RSI_14 | 44.9 | Neutral |
| MACD Histogram | -0.25 | Bearish |
| vs SMA20 | 0.982x | Below |
| vs SMA50 | 0.988x | Below |
| vs SMA200 | 0.897x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $77.25
- **Stop Loss:** $74.31 (3.8% risk)
- **Target:** $80.19 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 469
- **Position Value:** $36,230.25
- **Portfolio %:** 36.23%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-01-30 (Est: $0.91)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.89 | $0.91 | +2.4% |
| 2025Q2 | $0.89 | $0.92 | +2.8% |
| 2025Q1 | $0.86 | $0.91 | +6.1% |
| 2024Q4 | $0.89 | $0.91 | +2.3% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*